8-K: BioCardia Reports 2024 Financial Results and Business Highlights, Anticipates Key Data Readout

BioCardia announces its 2024 financial results, highlighting reduced operating losses and R&D expenses, and anticipates presenting CardiAMP HF Trial data at the American College of Cardiology Scientific Sessions.

Summary

• BioCardia reported its financial results for the year ended December 31, 2024.
• Net cash used in operations decreased to approximately $8.0 million in 2024 from $10.0 million in 2023.
• Revenues decreased to approximately $58,000 in 2024 from $477,000 in 2023.
• Research and development expenses decreased to approximately $4.4 million in 2024 from $7.7 million in 2023.
• Selling, general, and administrative expenses decreased to approximately $3.7 million in 2024 from $4.4 million in 2023.
• The company's net loss decreased to approximately $7.9 million in 2024 from $11.6 million in 2023.
• The company ended the year with cash and cash equivalents totaling $2.4 million.
• The company is preparing to present results from the CardiAMP HF Trial at the American College of Cardiology Scientific Sessions.
• The company plans to finalize the initial trial manuscript for publication and share the results with the FDA and Japan's PMDA.
• Enrollment activities in the CardiAMP HF II Trial are being accelerated.
• The last patient enrolled in the open-label roll-in cohort for CardiAMP in chronic myocardial ischemia reached their primary six-month endpoint in February 2025.
• Treatment of the low dose cohort of CardiALLO Cell Therapy has been completed with no treatment-emergent adverse events reported.
• The first commercial Morph DNA steerable introducer devices are now available.

Sentiment

Score: 7

Explanation: The sentiment is moderately positive. While revenue is down, the company has significantly reduced its losses and operating expenses. The upcoming data presentation and regulatory discussions are potential catalysts.

Positives

• Net loss decreased significantly from 2023 to 2024.
• Net cash used in operations decreased from $10.0 million to $8.0 million.
• Research and development expenses decreased due to the completion of the CardiAMP HF Trial.
• Selling, general and administrative expenses decreased due to realignment of personnel and cost reductions.
• The company is engaging with regulatory agencies (PMDA and FDA) regarding its CardiAMP Cell Therapy System.
• The CardiALLO Cell Therapy low dose cohort showed no treatment-emergent adverse events.
• The Morph Access Innovations business has launched its first commercial devices.

Negatives

• Revenues decreased significantly from 2023 to 2024.
• The company ended the year with $2.4 million in cash and cash equivalents, which may necessitate future capital raising.
• The company is still operating at a loss.

Risks

• The company's ability to raise additional funding is uncertain.
• Slower than targeted enrollment in clinical trials could delay completion and development of therapeutic candidates.
• Regulatory approvals for the company's products are not guaranteed.
• The company faces inherent uncertainties associated with developing new products and technologies.
• Unexpected expenditures could impact the company's financial performance.

Future Outlook

BioCardia anticipates several upcoming milestones and events, including presentations and publications of clinical trial data, regulatory submissions, and continued enrollment in clinical trials. The company also expects revenue from its Morph Access Innovations business and biotherapeutic delivery partnerships.

Management Comments

• We look forward to sharing the CardiAMP HF data at the American College of Cardiology Scientific Sessions this week, said BioCardia CEO Peter Altman, Ph.D.
• This data readout has potential to significantly de-risk development of our minimally invasive autologous cell therapy product candidate for patients with ischemic heart failure and may serve as the primary evidence to support product registration for market release.

Industry Context

BioCardia is operating in the competitive field of cell-based therapies for cardiovascular and pulmonary diseases. The company's focus on autologous and allogeneic cell therapies, combined with its delivery and navigation platforms, positions it to address unmet needs in the treatment of heart failure and myocardial ischemia.

Comparison to Industry Standards

• The company's cash burn of $8 million is relatively low compared to other clinical stage biotech companies.
• The company's revenue of $58,000 is low compared to other companies with commercial products.
• The company's net loss of $7.9 million is relatively low compared to other clinical stage biotech companies.

Stakeholder Impact

• Shareholders: Potential for positive impact from clinical trial data and regulatory progress, but risk of dilution from potential future capital raises.
• Employees: Realignment of personnel and cost reductions have already occurred, but future performance could impact job security.
• Patients: Potential for new treatment options for heart failure and myocardial ischemia.
• Business Partners: Opportunities for collaboration and revenue generation through biotherapeutic delivery partnerships and Morph Access Innovations.

Next Steps

• Presentation of CardiAMP HF Trial data at the American College of Cardiology Scientific Sessions on March 30, 2025.
• Finalizing the initial trial manuscript for publication.
• Sharing the CardiAMP HF Trial results with the FDA and Japan's PMDA.
• Accelerating enrollment activities in the CardiAMP HF II Trial.
• Submitting roll-in cohort data for CardiAMP in chronic myocardial ischemia for presentation/publication.
• Data Safety Monitoring Board review of completed low dose cohort for CardiALLO Cell Therapy.
• Pursuing biotherapeutic delivery partnerships.
• Generating revenues and case reports from the Morph Access Innovations business.

Key Dates

Keywords

CardiAMP, CardiALLO, BioCardia, Heart Failure, Cell Therapy, Clinical Trial, Financial Results, PMDA, FDA, Morph Access Innovations